Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Estcourt, Lise J ^a   Stanworth, Simon J ^a   Doree, Carolyn ^a   Hopewell, Sally ^b   Trivella, Marialena ^b   Murphy, Michael F ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; THROMBOCYTE CONCENTRATE;

APHERESIS; BLEEDING; BLOOD TRANSFUSION REACTION; CLINICAL PRACTICE; DISEASE SEVERITY; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HUMAN; INTERMETHOD COMPARISON; METHODOLOGY; MORTALITY; PATIENT SAFETY; PLATELET COUNT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VALIDITY; ADVERSE EFFECTS; BONE MARROW DISEASE; CHEMICALLY INDUCED; COMPLICATION; HEMATOLOGIC DISEASE; HEMORRHAGE; META ANALYSIS; STANDARDS; THROMBOCYTE COUNT;

ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; HEMATOLOGIC DISEASES; HEMORRHAGE; HUMANS; PLATELET COUNT; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 85017074785     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010983.pub2     Document Type: Review

References (302)

1. 9 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005;45:1064-72.
2. Heckman K, Weiner GJ, Strauss RG, Jones MP, Burns CP. Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood 1993;82(Abstract):192a.
3. 9/L. Journal of Clinical Oncology 1997;15:1143-9.
4. Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion 2004;44:1135-42.
5. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis 1997;78(Supplement):768-9.
6. 9/L platelets. Blood 1996;88(10):443a.
7. Heddle NM, Cook RJ, Sigouin C, Slichter SJ, Murphy M, Rebulla P. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion 2006;46:903-11.
8. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine 1997;337:1870-5.
9. Webert KE, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica 2006;91(11):1530-7.
10. Aderka D, Praff G, Santo M, Weinberger A, Pinkhas J. Bleeding due to thrombocytopenia in acute leukaemias and reevaluation of the prophylactic platelet transfusion policy. American Journal of the Medical Sciences 1986;291:147-51.
11. Agliastro RE, De Francisci G, Bonaccorso R, Spicola D, Ziino O, Arico M, et al. Clinical study in pediatric hemato-oncology patients: efficacy of pathogen inactivated platelets versus apheresis platelets. Transfusion 2006;46(9S):117A.
12. Akkök CA, Brinch L, Lauritzsen GF, Solheim BG, Kjelsden-Kragh J. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sanguinis 2007;93(1):42-8.
13. Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfusion Medicine 1997;7:33-9.
14. Andreu G, Vasse J, Tardivel R, Semana G. Platelet transfusion: products, indications, dose, threshold and efficacy. Transfusion Clinique Et Biologique 2009;16(2):118-33.
15. Andrew M, Vegh P, Caco C, Kirpalani H, Jefferies A, Ohlsson A, et al. A randomized controlled trial of platelet transfusions in thrombocytopenic premature infants. Journal of Pediatrics 1993;123(2):285-91.
16. Arnold DM, Heddle NM, Carruthers J, Kulczycky M, Sigouin C, Blajchman MA. A randomized crossover trial comparing in-vivo platelet recovery and survival of leukoreduced apheresis and whole blood derived platelets. Transfusion 2004;44(supplement):1A.
17. Arnold DM, Crowther MA, Cook RJ, Sigouin C, Heddle NM, Molnar L, et al. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion 2006;46(8):1286-91.
18. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Critical Reviews in Oncology/Hematology 2003;48(Suppl 1):S13-6.
19. Bai CM, Xu GX, Zhao YQ, Han SM, Shan YD. A multi-centre clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae 2004;26(4):437-41.
20. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?. Critical Reviews in Oncology/Hematology 2002;42(2):163-71.
21. Bentley M, Taylor K, Kelly C, Taylor D, Leach B, Rodwell R, et al. Thrombopoietin derived autologous cryopreserved platelet support for peripheral blood progenitor cell transplantation. Haematology Society of Australia and New Zealand Annual Scientific Meeting. Perth, July 23-26 2000.
22. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;2008:198-204.
23. Blumberg N, Heal JM, Rowe JM. Platelet transfusion and clinical outcome in acute leukemia in adults. Transfusion 2002;42(9S):5S.
24. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]. BMC Blood Disorders 2004; Vol. 4, issue 6. [DOI: 10.1186/1471-2326-4-6]
25. Blundell EL, Pamphilon DH, Fraser ID, Kagen L, Menitove JE, Aster RH, et al. A prospective randomised study of platelet concentrates irradiated with ultraviolet (UV)-B light in patients with high grade haematological malignancy. Blood 1992;80(10):215A.
26. Blundell EL, Pamphilon DH, Fraser ID, Menitove JE, Greeenwalt TJ, Snyder EL, et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996;36(4):296-302.
27. Buhrkuhl DC. An update on platelet transfusion in hematooncology supportive care. Transfusion 2010;50(10):2266-76.
28. Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. British Journal of Haematology 2002;118:677-82.
29. Cameron B, Rock G, Olberg B, Neurath D. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion 2007;47(2):206-11.
30. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. British Journal of Haematology 1990;75:408-13.
31. Casbard AC, Williamson LM, Murphy MF, Rege K, Johnson T. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 2004;59(6):550-8.
32. Chaoui D, Chakroun T, Robert F, Rio B, Belhocine R, Legrand O, et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion 2005;45(5):766-72.
33. Chaurasia R, Elhence P, Nityanand S, Verma A. 'Bleeding' and 'transfusion support' in acute myeloid leukemia patients: the challenges. Indian Journal of Hematology and Blood Transfusion 2012;28(4):249-50.
34. Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion 2007;47:464-70.
35. Corash L, Klueter H, Rhenen D, Gullikson H, Pamphilon D, Cazenave JP, et al. Intercept platelet concentrates (IPC) are effective and safe for support of multiple cycles of thrombocytopenia: the eurosprite phase III trial. Hematology Journal 2001;2(Supplement 1):178-9.
36. Couban S, Carruthers J, Andreou P, Klama LN, Barr R, Kelton JG, et al. Platelet transfusions in children: results of a randomised prospective cross-over trial of plasma removal and a prospective audit of WBC reduction. Transfusion 2002;42:753-8.
37. Decaudin D, Vantelon JM, Bourhis JH, Farace F, Bonnet ML, Guillier M, et al. Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma. Bone Marrow Transplantation 2004;34(12):1089-93.
38. De Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk KM, Bins M, van Prooijen HC, et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000;40(4):398-403.
39. Diedrich B, Ringden O, Watz E, Shanwell A. A randomised study of buffy coat platelets in platelet additive solution 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic cell transplant recipients. Vox Sanguinis 2009;97(3):254-9.
40. Diedrich B, Watz E, Ringden O, Shanwell A. A randomized study in allogeneic haematopoietic stem cell transplant recipients comparing prophylactic transfusion of buffy coat platelets stored for 1-5 vs. 6-7 days. Vox Sanguinis 2008;95(Supp 1):Abstract.
41. Di Pietro G, Menicucci A, Venturini S, Graziani G, Sani R, Avanzi G. Platelet transfusion support during bone marrow transplantation. Comparative study between the use of HLA platelet apheresis and random platelet apheresis. Trasfusione del Sangue 1998;43(1):47-50.
42. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, et al. A randomized controlled trial comparing autologous radiolabeled in vivo platelet(plt) recoveries and survivals of 7-day-stored plt-rich plasma and buffy coat plts from the same subjects. Transfusion 51;6:1241-8.
43. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Current Hematology Reports 2004;3(5):324-30.
44. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross Experience (2004-2006). Transfusion 2007;47(7):1134-42.
45. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, et al. The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer 2002;94(12):3252-62.
46. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003;97(6):1541-50.
47. Fanning J, Hilgers RD, Murray KP, Bolt K, Aughenbaugh DM. Conservative management of chemotherapy-induced thrombocytopenia in women with gynecological cancers. Gynecologic Oncology 1995;59:191-3.
48. Follea G. Homologous platelet concentrates: products available and utilisation rules in oncology and haematology. Hematologie 2004;10(3):233-44.
49. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients?. Transfusion Medicine Reviews 2002;16:34-45.
50. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for non-bleeding patients in the intensive care unit: Benefit or harm?. Critical Care Medicine 2006;35(5 Suppl):S170-3.
51. Gerday E, Baer VL, Lambert DK, Pau DA, Sola-Visner MC, Pysher TJ, et al. Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit. Transfusion 2009;49:2034-9.
52. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, Pinilla I, Gomez Garcia V, Martinez C, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplantation 1996;18:931-5.
53. Gmür J, von Felten A, Osterwalder B, Honegger H, Hermann A, Sauter C, et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62(2):473-9.
54. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. The Lancet 1991;338:1223-6.
55. Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001;98(5):1346-51.
56. Goodnough LT, DiPersio JFD. Issues in the management of cancer-related thrombocytopenia. Oncology 2002;16(11):1558-67.
57. Goodnough LT. Risks of blood transfusion. Anesthesiology Clinics of North America 2005;23(2):241-52.
58. Goodrich R, Follua G, Roberts T. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008;48(S2):20A.
59. Greeno E, McCullough J, Weisdorf D. Platelet utilisation and the transfusion trigger: A prospective analysis. Transfusion 2007;72(2):201-5.
60. Grossman L, Mangal A, Hislop TG, Buskard NA. Preliminary report on a randomized study of prophylactic (P) vs. therapeutic (T) platelet transfusions. Blood 1980;80:271.
61. Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 2007;40(5):461-4.
62. Hardan I, Sofer O, Shpilberg O, Ra'anani P, Ben-Bassat I. Safety of stringent prophylactic platelet transfusion (PT) policy for lymphoma patients treated by high dose chemotherapy (HDC) and autologous stem cell support. [20th Annual Meeting of the European Group for Bone Marrow Transplantation and 10th Meeting of the Nurses Group]. Bone Marrow Transplant 1994;14(Supplement):Abstract 330.
63. Harrup RA, Kennedy JT, Kiss J, Daniels B. Randomised blinded comparison of buffy coat plasma or T-sol supported platelet transfusions. Haematology Society of Australia and New Zealand Annual Scientific Meeting. Hobart; Tasmania, October 1999.
64. Heal J, Kemmotsu N, Rowe J, Blumberg N. A survival advantage in leukaemics receiving ABO identical platelets. Blood 1991;78:349a.
65. Heal J, Rowe J, Blumberg N. The importance of ABO identical platelet transfusions. Blood 1991;78:348a.
66. Heal J, Rowe J, McMican A, Finke K, Blumberg N. A randomised trial of ABO identical versus ABO unmatched platelet transfusions. Blood 1989;74(7 Supp 1):215a.
67. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N. The role of ABO matching in platelet transfusion. European Journal of Haematology 1993;50:110-7.
68. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Reviews 2004;18(3):149-65.
69. Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, et al. The role of the plasma from platelet concentrates in transfusion reactions. The New England Journal of Medicine 1994;331(10):625-8.
70. Heddle NM, Klama L, Meyer R, Walker I, Boshkov L, Roberts R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999;39(3):231-8.
71. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002;42(5):556-66.
72. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003;43:742-52.
73. Heddle NM, Cook RJ, Blajchman MA, Barty RL, Sigouin CS, Boye DM, et al. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion 2005;45(6):896-903.
74. Heddle NM. Controversy concerning platelet dose. ISBT Science Series, Vol 2, No 1: State of the Art Presentations 2007;2:220-5.
75. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113(7):1564-73.
76. Heddle NM, Wu C, Vassallo R, Carey P, Arnold D, Lozano M, et al. Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion 2011;51:2304-10.
77. NCT00420914 Strategies for Transfusion of Platelets (SToP). http://clinicaltrials.gov/show/NCT00420914 (accessed 15 September 2009).
78. Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 1974;14:440-5.
79. ISRCTN01292427 Comparison of in vivo outcome following transfusion of dynamic light scattering-screened versus unscreened platelets in hematologic malignancy. www.controlled-trials.com/ISRCTN01292427 (accessed 16 June 2014).
80. ISRCTN49080246 Platelet Process Improvement Project. http://www.controlled-trials.com/ISRCTN49080246 (accessed 16 June 2011).
81. ISRCTN56366401 Platelet responsiveness and outcome from platelet transfusion - does inherent variation in donor platelet function affect the clinical efficacy of apheresis platelets? A randomised double blind single centre trial. UK Clinical Research Network (UKCRN) http://www.controlled-trials.com/ISRCTN56366401 (accessed 16 June 2014).
82. Jelic S, Radulovic S. Chemotherapy-associated thrombocytopenia current and emerging management strategies. American Journal of Cancer 2006;5(6):371-82.
83. Johansson PI, Stensballe J, Rosenberg I, Hisløv TL, Jørgensen L, Secher NH. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 2007;47(4):593-8.
84. Julmy F, Ammann RA, Taleghani BM, Fontana S, Hirt A, Leibundgut K. Transfusion efficacy of ABO major-mismatched platelets (PLTS) in children is inferior to that of ABO-identical platelets. Transfusion 2009;91(1):21-33.
85. Kakaiya RM, Hezzey AJ, Bove JR, Katz AJ, Genco PV, Buchholz DH, et al. Alloimmunization following apheresis platelets vs. pooled platelet concentrates. A prospective randomized study. Transfusion 1981;21(5):600.
86. Kerkhoffs JH, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus I, et al. Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients. Transfusion 2009;49(s3):2A.
87. Kerkhoffs JLH, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology 2010;150(2):209-17.
88. Ackerman SJ, Klumpp TR, Guzman GI, Herman JH, Gaughan JP, Bleecker GC, et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 2000;40(12):1457-62.
89. Hermann JH, Klumpp TR, Christman RA, Russo RR, Goldberg SL, Mangan KF. The effect of platelet dose on the outcome of prophylactic platelet transfusion. Transfusion 1995;35(10s):46S.
90. Klumpp T, Herman JH, Christman RA, Russo RR, Goldberg SL, MacDonald JS, et al. The effect of platelet dose on the interval between platelet transfusions in patients undergoing bone marrow or peripheral blood stem cell transplantation. Proceedings of American Society of Clinical Oncology (ASCO). 1995:536.
91. Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL, et al. Clinical consequences of alterations in platelet dose: a prospective, randomized, double-blind trial. Transfusion 1999;39:674-81.
92. Kluter H, Dorges L, Maass E, Wagner T, Bartels H, Kirchner H. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Annals of Hematology 1996;73(2):85-9.
93. Lapierre V, Benhamou E, Tramalloni D, Brault P, Valteau-Couanet D, Ducourtieux M, et al. A randomised trial of platelet transfusion policies after blood stem cell transplantation in young children: reduction of number of single platelet concentrate donors per child. Bone Marrow Transplantation 2003;31(Supplement 1):P756.
94. Lawrence JB, Yomtovian RA, Hammons T, Masarik SR, Chongkolwatana V, Cregar RJ, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leukemia & Lymphoma 2001;41:67-76.
95. Leach MF, Fairweather RB, Aubuchon JP. Use of warmed single donor platelets in autologous bone marrow transplant patients. Transfusion 1991;31(Suppl):20S.
96. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989;29(5):384-9.
97. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. International Journal of Hematology 2002;76(Suppl 2):139-44.
98. Lordkipanidze M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacology & Therapeutics 2009;123(2):178-86.
99. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh[D) incompatibility. Transfusion Medicine Reviews 2003;17(1):57-68.
100. Lozano M, Knutson F, Tardivel R, Cid J, Maymó R, Löf H, et al. Frequency of prophylactic transfusion failure: a novel outcome to evaluate platelet components stored more than 5 days. Transfusion 2010;50(Supp 2):25A-6A.
101. Lozano M, Knutson F, Tardivel R, Cid J, Maymó RM, Löf H, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotsalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. British Journal of Haematology 2011;153(3):393-401.
102. Lu FQ, An WX, Kang W, Zhang YL. Effect of reducing prophylactic platelet transfusion dose on bleeding in thrombocytopenia patients [Chinese Source]. International Journal of Blood Transfusion and Hematology 2011;34(4):295-8.
103. Lu FQ, Wang WM, Yu M. Effect of reducing prophylactic platelet transfusion dose on bleeding in thrombocytopenic patients. Vox Sanguinis 2011;101(S1):310 (P-577).
104. Martel N, Wells PS. A meta-analysis to determine the risk of heparin induced thrombocytopenia (HIT) and isolated thrombocytopenia in prophylaxis studies comparing unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Blood 2004;104(11):708a-9a.
105. Benjamin RJ, Goodnough LT, Lopez-Perez I, Strauss R, McCullough J, Slichter S, et al. Fresh (1-2 day-old) vs. aged (4-5 day-old) INTERCEPT platelets and conventional platelets provide comparable count increments. However fresh platelets result in superior hemostasis: results of the SPRINT trial. Transfusion 2003;43(9S):9A.
106. Corash L, Lin JS, Sherman CD, Eiden J. Determination of acute lung injury following repeated platelet transfusions. Blood 2010; Vol. 117, issue 3:1014-20. [PUBMED: 20935256]
107. 9/L is associated with increased pre-transfusion bleeding and increased platelet transfusions: results of the SPRINT study. Transfusion 2002;42(9S):17S.
108. Kluter H, Chapuis B, Cazenave J, Hastka J, Beris P, Dufour P, et al. Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets. Vox Sanguinis 2002;83(Suppl 1):110a.
109. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Synder E, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104(5):1534-41.
110. Murphy S, Slichter S, McCullough J, Strauss R, Wood L, Lin J, et al. INTERCEPT platelets are hemostatically as effective as conventional platelet in the prophylaxis and treatment of bleeding: results of the SPRINT trial. Vox Sanguinis 2002;83(109):Abstract.
111. Murphy S, Synder E, Cable R, Slichter SJ, Strauss RG, McCullough J, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006;46(1):24-33.
112. Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, et al. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion 2006;46(4):562-71. [PUBMED: 16584432]
113. Slichter SJ, Murphy S, Buchholz D, Lin J, Corash L, Conlan M. INTERCEPT platelets (plts) and conventional plts provide comparable hemostatic response in thrombocytopenic patients: the SPRINT trial. Blood 2002;11(Pt 2):141b.
114. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; Vol. 45, issue 12:1864-75. [PUBMED: 16371039]
115. Strauss RG, Slichter S, Lopez-Plaza I, Goodnough LT, McCullough J, Lin J, et al. Intercept platelets exhibit immunological refractoriness comparable to conventional platelets. Haematologica 2004;89(Suppl 1):Abstract.
116. Vesole D, Stadtmauer E, Goodnough LT, Coutre S, Howard F, Lin JS, et al. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the Phase III SPRINT trial of INTERCEPT pathogen inactivated platelets. Biology of Blood and Bone Marrow Transplantation 2004; Vol. 10, issue 2:233.
117. McNicol A, Israels SJ. Platelets and platelet therapy. Journal of Pharmacological Sciences 2003;93(4):381-96.
118. Messerschmidt GL, Makuch R, Appelbaum F, Ungerleider RS, Abrams R, O'Donnell J, et al. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients. Cancer 1988;62(4):795-801.
119. Ambruso DR, Thurman G, Marschner S, Goodrich RP. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 2009;49(12):2631-6. [PUBMED: 19694996]
120. Goodrich R, Roberts T, Follea G. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008;48(Suppl):20A. Abstract No. S49-020G.
121. The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
122. Murphy S, Litwin S, Herring LM, Koch P, Remischovky J, Donaldson MH, et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology 1982;12:347-56.
123. Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. British Journal of Haematology 1986;62:529-34.
124. Navarro J-T, Hernandez J-A, Ribera J-M, Sancho J-M, Oriol A, Pujol M, et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10, 000/mL. Haematologica 1998;83:998-1000.
125. NCT00699621 Platelet transfusion in acute intracerebral haemorrhage. https://clinicaltrials.gov/ct2/show/NCT00699621 (accessed 14 April 2010).
126. NCT01615146 Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot. http://ClinicalTrials.gov/show/NCT01615146 (accessed 16 April 2013).
127. 9 per L. Transfusion 2007;47:801-12.
128. Norol F, Bierling P, Roudot-Thoraval F, Ferrer Le Coeur F, Rieux C, Lavaux A, et al. Platelet transfusion: a dose response study. Blood 1998;92:1448-53.
129. Norville R, Hinds P, Wilimas J, Fairclough D, Fischl S, Kunkel K. The effects of infusion methods on platelet count, morphology, and corrected count increment in children with cancer: in vitro and in vivo studies. Oncology Nursing Forum 1994;21(10):1669-73.
130. Norville R, Hinds P, Wilimas J, Fischl S, Kunkel K, Fairclough D. The effects of infusion rate on platelet outcomes and patient responses in children with cancer: an in vitro and in vivo study. Oncology Nursing Forum 1997;24(10):1789-93.
131. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components: A randomized trial. Transfusion 1991;31:588-94.
132. Oksanen K, Ebeling F, Kekomäki R, Elonen E, Sahlstedt L, Volin L, et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sanguinis 1994;67(4):356-61.
133. Paananen P, Arola MO, Pelliniemi TT, Salmi TT, Lähteenmäki PM. Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia. Journal of Pediatric Haematology/Oncology 2009;31(10):745-9.
134. Pamphilon DH. Comparative clinical studies of platelet concentrates: Effects on clinical outcome and the use of healthcare resources. Transfusion Science 1996;17(3):343-6.
135. Paramo JA, Lecumberri R, Hernandez M, Rocha E. Pharmacological alternatives to blood transfusion: what is new about?. Medicina Clinica 2004;122(6):231-6.
136. Poon MC. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?. Current Hematology Reports 2003;2(2):139-47.
137. Qureshi H, Lowe D, Dobson P, Grant-Casey J, Parris E, Dalton D, et al. National comparative audit of the use of platelet transfusions in the UK. Transfusion Clinique Et Biologique 2007;14(6):509-13.
138. Rabinowitz I. Dose of prophylactic platelet transfusions did not affect bleeding incidence or severity. ACP Journal Club 2010;152(6):11.
139. Rayment R, Brunskill SJ, Stanworth S, Soothill PW, Roberts DJ, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004226.pub2]
140. Razzaghi A, Barkun A. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. Journal of Clinical Gastroenterology 2012;46(6):482-6.
141. Rebulla P, Grazzini G, Liumbruno GM, Aprili G, Formisano S, Girelli G, et al [The Italian Platelet Technology Assessment Study (IPTAS) Research Group]. Pathogen inactivated platelets and prevention of immunological adverse reactions: the Italian Platelet Technology Assessment Study (IPTAS). Blood Transfusion 2009;7, Suppl 1: 11th European Haemovigilance Seminar:Abstract No. LE08. (Abstract freely available at: http://www.bloodtransfusion.it/articoli/47/en/Doi%200013.pdf. Date accessed: 18 February 2013). [DOI: 10.2450/2009.0013-09]
142. Reed RL, Ciavarella D, Heimbach DM, Baron L, Pavlin E, Counts RB, et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Annals of Surgery 1986;203(1):40-8.
143. Roberts IAG, Murray NA. Thrombocytopenia in the newborn. Current Opinion in Pediatrics 2003;15(1):17-23.
144. Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusion in children with acute leukemia: A dose response study. Transfusion 1973;13(5):283-90.
145. Sagmeister M, Oec L, Gmur J. A restrictive platelet transfusion policy allowing long term support of outpatients with severe aplastic anaemia. Blood 1999;93:3124-6.
146. Sakakura M, Wada H. Prevention of hemorrhage occurring in patients with leukemia. Zassh (Nippon-Naika-Gakkai-Zasshi) 2003;92(6):1025-9.
147. Samama CM, Djoudi R, Lecompte T, Nathan DN, Schved JF. Perioperative platelet transfusion: recommendations of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSaPS) 2003. Canadian Journal of Anaesthesia 2005;52(1):30-7.
148. Samama CM, Djoudi R, Lecompte T, Nathan N, Schved JF. Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. Minerva Anestesiologica 2006;72(6):447-52.
149. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815-20.
150. Sensebe L, Giraudeau B, Bardiaux L, Deconninck E, Ifrah N, Bidet M-L, et al. Increasing dose improves the platelet transfusions: results of a prospective multicentre randomised study. Blood 2002;100:(Abstract 2789) 708a.
151. Sensebe L, Giraudeau B, Baridaux L, Deconinck E, Schmidt A, Bidet ML, et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2004;105:862-4.
152. Shanwell A, Larsson S, Aschan J, Ringden O. A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients. European Journal of Haematology 1992;49(2):77-81.
153. Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K. ABO-identical versus non-identical platelet transfusion: a systematic review. Transfusion 2009;49:2442-53.
154. Shen Y-MP, Frenkel EP. Acquired platelet dysfunction. Hematology/Oncology Clinics of North America 2007;21(4):647-61.
155. Singer J, Ali AM, Warkentin TE, Blajchman MA, Kelton JG. A prospective randomized study of platelet support in leukemic patients. Transfusion 1988;72(5 Supp):285A.
156. Sintnicolaas K, Vriesendorp HM, Sizoo W, Stenfert Kroese WF, Haije WG, Hop WC, et al. Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. The Lancet 1981;1(8223):750-4.
157. Sintnicolaas K, Velden K, Sizoo W, Haije WG, Abels J, Lowenberg B. Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology 1982;50:684.
158. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: A randomized prospective study. Blood 1995;85:824-8.
159. Slichter SJ, Grabowski M, Townsend-McCall D, Bolgiano D. Prospective randomized transfusion trial to directly compare fresh and stored apheresis platelets (AP) and pooled random donor platelet concentrates (PC) in thrombocytopenic patients. Blood 1998;92:Abstract.
160. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Medicine Reviews 2004;18(3):153-67.
161. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, et al. Platelets photochemically treated with amotsalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46(5):731-40.
162. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology 2007;2007:172-8.
163. Assman S, Triulzi DJ, McCullough J, Harrison RW, Slichter SJ. Cost tradeoffs of low-, medium-, and high-dose platelet transfusions. Transfusion 2013;53(Supplement):188A.
164. Josephson C, Sloan S, Granger S, Castillejo M, Strauss RG, Slichter S, et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion 2009;49(S3):19A-20A.
165. Josephson CD, Granger S, Assmann SF, Castillejo M-I, Strauss RG, Slichter SJ, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012;120(4):748-60.
166. Kaufman RM, Assmann SF, Triulzi DJ, Strauss RG, Ness P, Granger S, et al. Transfusion-related adverse events in the platelet dose study. Transfusion 2015;55(1):144-53.
167. NCT00128713 Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713 (accessed 16 April 2010).
168. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis 2006;21:78-84.
169. Slichter SJ, Kaufman RM, Assman SF, Brecher ME, Gernsheimer T, Hillyer CD, et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood 2008;112(11):Abstract 285.
170. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine 2010;362:600-13.
171. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess J, Granger S, et al. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion 2010;50(Supplement):3A.
172. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, et al. The impact of platelet transfusion characteristics on post-transfusion platelet increments and clinical bleeding in patients with hypo-proliferative thrombocytopenia. Blood 2012;119(23):5553-62.
173. Slichter SJ. Effects of platelet (Plt) dose on transfusion outcomes. Transfusion Medicine 2012;22:227.
174. Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutler E. Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet 1978;1 (8058):267.
175. Sosa MEB. Alloimmune thrombocytopenia in the fetus: current management theories. The Journal of Perinatal & Neonatal Nursing 2003;17(3):181-9.
176. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004;44(8):1143-8.
177. Campbell HE, Estcourt LJ, Stokes EA, Llewelyn CA, Murphy MF, Wood EM, et al. TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion 2014;54(10):2394-403.
178. ISRCTN08758735 A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735 (accessed 6 February 2010).
179. Powter G, Dyer C, Bielby L. Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions - how was consistency achieved [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. Transfusion Medicine 2013;23:46-7.
180. Stanworth SJ, Dyer C, Choo L, Bakrania L, Copplestone A, Llewelyn C, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews 2010;24(3):163-71.
181. Stanworth SJ, Estcourt L, Powter G, Kahan BC, Dyer C, Bakrania L, et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood 2012;120(Supplement 1):Abstract 1.
182. Stanworth SJ, Estcourt LJ, Llewelyn CA, Murphy MF, Wood EM, TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion 2014;54(10):2385-93.
183. Stanworth SJ, Estcourt LJ, Powter G, Kahan B, Dyer C, Choo L, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. The New England Journal of Medicine 2013;368(19):1771-80.
184. Stanworth SJ, Hudson CL, Estcourt LJ, Johnson RJ, Wood EM. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica 2015;100(6):740-7.
185. Wood EM, Hudson C, Estcourt L, Johnson R, Stanworth SJ. Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood 2014;124(21):Abstract.
186. Steffens I, Harrison JF, Taylor CPF. A dose response study of platelet transfusion: comparison between triple dose apheresis platelet transfusion and three split standard transfusions. Haematologica 2002;87(Suppl 1):Abstract.
187. Strauss RG. Low-dose prophylactic platelet transfusions: Time for further study, but too early for routine clinical practice. Transfusion 2004;44(12):1680-2.
188. Strauss RG. Pretransfusion trigger platelet counts and dose for prophylactic platelet transfusions. Current Opinion in Hematology 2005;12(6):499-502.
189. Strindberg J, Berlin G. Transfusion of platelet concentrates - clinical evaluation of two preparations. European Journal of Haematology 1996;57(4):307-11.
190. Sweeney JD, Kouttab NM, Penn CL, McHugh KE, Nelson EJ, Oblon DJ. A comparison of prestorage WBC-reduced whole blood derived platelets in autologous progenitor cell transplant. Transfusion 2000;40(7):794-800.
191. Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfusion Medicine Reviews 2003;17(3):181-93.
192. Tinmouth A, Kotchetkova N, Tomlinson G, Crump M, Brandwein J, Tannock I, et al. A randomised phase II trial of low dose and standard dose platelet transfusions during induction therapy for acute leukemia or autologous stem cell transplantation. Vox Sanguinis 2002;83(Suppl 1):8.
193. Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M, et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor transplant and patients with acute leukaemia: a randomized controlled trial with a sequential Bayesian design. Transfusion Medicine 2004;44:1711-9.
194. Tosetto A, Balduini CL, Cattaneo M, De Candia E, Mariani G, Molman AC, et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research 2009;125(5):e13-8.
195. Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003;43(11):1545-52.
196. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105(10):4106-14.
197. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The New England Journal of Medicine 1997;337:1861-70.
198. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. The Lancet 2002;359:2145-52.
199. Van Marwijk KM, van Prooijen HC, Moes M, Bosma-stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 1991;77:201-5.
200. Cazenave JP, Davis K, Corash L. Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Seminars in Hematology 2001;38(4 Supp 11):46-54.
201. Cazenave JP, van Rhenen D, Gulliksson H, Pamphilon D, Ljungman P, Davis K, et al. INTERCEPT buffy coat platelets (IPC) are effective during multiple episodes of thrombocytopenia: the EUROSPRITE trial. Transfusion Clinique et Biologique 2001;8(Supp 1):Various.
202. Ljungman P, van Rhenen D, Pamphilon D, Metzel P, Marblie S, Lin J, et al. Results of the EUROSPRITE phase III trial: INTERCEPT buffy coat platelet concentrates (IPC) provide effective hemostasis for thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique 2001;8(Supp 1):100s.
203. Pamphilon D, Buchholz DH, Cazenave JP, Conlan M, Corash L, Davis K, et al. The EUROSPRITE phase III trial of INTERCEPT buffy coat platelet concentrates (IPC) demonstrates IPC are safe when transfused to thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique 2001;8(Supp 1):100-1s.
204. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101(6):2426-33.
205. Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, et al. The effect of fibrinogen concentrate on thrombocytopenia. Journal of Thrombosis and Haemostasis 2007;5(5):1019-25.
206. Verma A, Pandey P, Khetan D, Chaudhary R. Platelet transfusions in clinical practice at a multidisciplinary hospital in North India. Transfusion and Apheresis Science 2008;39(1):29-35.
207. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukaemia. Blood 1998;91:3601-6.
208. Wandt H, Frank M, Link H, Schneider C, Brack N, Daoud A, et al. The 10/NL trigger for prophylactic platelet transfusion in AML: a prospective comparative multicenter study. Annals of Hematology 1995;70(Suppl 1):A140.
209. Wandt H, Frank M, Schaefer-Eckart K, Wilhelm M. Routine prophylactic platelet transfusions are not necessary in patients with acute myeloid leukaemia. A therapeutic transfusion strategy is safe. Blood 2005;106(11):Abstract.
210. Wandt H, Reinel H, Schaefer-Eckart K, Wilhelm M, Birkmann J, Gallmeier WM. New strategy for platelet transfusion for patients with acute myeloid leukaemia: routine prophylactic transfusion replaced by therapeutic transfusion. Blood 2002;100((Abstract 2782)):706a.
211. Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37(4):387-92.
212. Wandt H. Indication for platelet transfusion in patients with haematological disease: less is more. [German]. Deutsche Medizinische Wochenschrift 2010;135(38):1877-9.
213. NCT00521664 A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664 (accessed 4 January 2010).
214. Schaefer-Eckart K, Wendelin K, Pilz B, Kramer M, Ehninger G, Wilhelm M, et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood 2014;124(21):Abstract.
215. Schaefer-Eckart K, Wendelin K, Wilhelm M, Mahlknecht U, Conradi R, Schaich M, et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood 2006;108(11):Abstract.
216. Wandt H, Schaefer-Eckart K, Pilz B, Thalheimer M, Ho A, Schaich M, et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie 2010;33(6):Abstract.
217. Wandt H, Schaefer-Eckart K, Pilz B, Thalheimer M, Ho AD, Schaich M, et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood 2009;11(Supplement):Abstract.
218. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet 2012;380(9850):1309-16.
219. Wandt H, Schäfer-Eckart K, Wendelin K, Rottmann M, Thalmeimer M, Schubert MS, et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation 2009;43 Supp 1:S23.
220. Wandt H, Wendelin K, Schaefer-Eckart K, Thalheimer M, Schubert MS, Conradi R, et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract 286.
221. Wang SE, Lara PN, Lee OA, Reed J, Wang LR, Palmer P, et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. American Journal of Hematology 2002;70(3):191-4.
222. Wang XQ. Using evidence-based guideline for prophylactic platelet transfusion in patient with myelodysplastic syndrome. Chinese Journal of Evidence-Based Medicine 2005;5(6):482-4.
223. Weigand K, Encke J, Meyer FJ, Hinkel UP, Munder M, Stremmel W, et al. Low levels of prothrombin (INR) and platelets do not increase the risk of significant bleeding when placing central venous catheters. Medizinische Klinik 2009;104(5):331-5.
224. Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, Gooi HC, Morgenstern GR, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization: A prospective randomized study. Alloimmunization Study Group. Blood 1994;83:3028-35.
225. Woodard P, Lubin B, Walters CMC. New approaches to hematopoietic cell transplantation for hematological diseases in children. Pediatric Clinics of North America 2002;49(5):989-1007.
226. Zahur UR, Alam M. Platelet transfusion practice in a tertiary care hospital. Medical Forum Monthly 2002;13(7):27-9.
227. Zeller MP, Al-Habsia KS, Heddle NM. Prophylactic platelet transfusions: should they be a treatment of the past?. Current Opinion in Hematology 2014;21(6):521-7.
228. Zhao SM, Cheng XL, Hu J, Xiang GC, Zhang JS, Li RQ. Clinical assessment of preventing febrile nonhemolytic transfusion reaction by leucocyte depleted blood transfusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002;10(6):568-70.
229. Zumberg MS, Rosario ML, Pollock BH, Nejame CF, Allen LS, Boyette R, et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10, 000μL vs. an 20, 000 μL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12-15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001.
230. Zumberg MS, del Roario ML, Nejame CF, Pollock BH, Garzarella L, Kao KJ, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10, 000/μL versus 20, 000/μL trigger. Biology of Blood and Marrow Transplantation 2002;8:569-76.
231. Ajani JA, Welsh SR, Raber MN. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investigation 1990;8:141-53.
232. British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology 2003;122:10-23.
233. British Committee for Standards in Haematology (BCSH). Transfusion guidelines for neonates and older children. British Journal of Haematology 2004;124(4):433-53.
234. Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. British Journal of Haematology 2009;147(4):431-43.
235. Beutler E. Platelet transfusions: the 20, 000/μL trigger. Blood 1993;81:1411-3.
236. Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell - CD40 ligand and transfusion immune modulation. Immunology Research 2009;45:251-60.
237. The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board. Platelet concentrates. Cross-sectional guidelines for therapy with blood components and plasma derivatives. Transfusion Medicine and Hemotherapy 2009;36:372-82.
238. Bolton-Maggs PHB (Ed) and H Cohen on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2012.
239. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology 2011;29(4):369-77.
240. Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD009072]
241. Cancer Research UK. Percentage change in European age-standardised three year average incidence rates, males, UK, 1991-2001 and 2008-2010. Cancer Research UK statistics at http://www.cancerresearchuk.org/cancer-info/cancerstats/ (accessed 14 February 2013).
242. CDC (Centers for Disease Control and Prevention). United States Cancer Statistics. National Program of Cancer Registries (NPCR) http://www.cdc.gov/cancer/npcr/ 2012 (accessed 14 February 2013).
243. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer 2004;90(7):1367-73.
244. Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers. Transfusion 2004;44:1135-42.
245. De la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008;111(7):3395-402.
246. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
247. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of 3 cases of hemorrhagic disease relieved by transfusion. Journal of the American Medical Association 1910;55:1185-92.
248. Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them?. British Journal of Haematology 2011;154(4):425-40.
249. Estcourt LJ, Birchall J, Lowe D, Grant-Casey J, Rowley M, Murphy MF. Platelet transfusions in haematology patients: are we using them appropriately?. Vox Sanguinis 2012;103(4):284-93.
250. Estcourt LJ, Heddle N, Kaufman RM, McCullough J, Murphy MF, Slichter S, et al. On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013;53(7):1531-43.
251. Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Murphy MF, et al. Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD010984]
252. Estcourt LJ, Gregg R, Stanworth S, Doree C, Trivella M, Murphy MF, et al. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD010982]
253. Estcourt LJ, Crighton GL, Wood EM, Stanworth S, Trivella M, Doree C, et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD010981]
254. Estcourt LJ, Pinchon D, Symington E, Kelly AM, Doree C, Brunskill S, et al. Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion 2014;54(4):1166-79. [DOI: 10.1111/trf.12441]
255. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109(3):944-50. [PUBMED: 17032921]
256. Freedman L, Sylvester R, Byar DP. Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials. Controlled Clinical Trials 1989;10:129-41.
257. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukaemia. The New England Journal of Medicine 1962;266:905-9.
258. McMaster University. GRADEpro [www.gradepro.org]. McMaster University, 2015.
259. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303(16):1617-24.
260. Harrison P, Ault KA, Chapman S, Charie L, Davis B, Fujimoto K, et al. An interlaboratory study of a candidate reference method for platelet counting. American Journal of Clinical Pathology 2001;115:448-59.
261. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008;48(7):1447-58.
262. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113(7):1564-73.
263. Heddle NM, Webbert K. Investigation of acute transfusion reactions. In: Murphy MF, Pamphilion DH editor(s). Practical Transfusion Medicine. 4th Edition. Blackwell, 2009:63-89.
264. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
265. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
266. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
267. Knowles S (Ed), Cohen H, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2011.
268. Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion 2004;44:605-17.
269. Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AAR, Kleinman S, et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2015;55(5):1116-27.
270. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
271. National Blood Authority. The National Blood Authority's Patient Blood Management Guideline: Module 3 - Medical. National Blood Authority, 2012.
272. Office for National Statistics. Cancer incidence and mortality tables and charts. http://www.ons.gov.uk/ons/index.html 2012 (accessed 14 February 2013), issue tcm77-259491.
273. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
274. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47(7):906-23.
275. Patel B, Kirkland K, Szydlo R, Pearce R, Clark R, Craddock C, et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009;94:1399-406.
276. Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, et al. International Collaboration for Guideline Development, Implementation. Evaluation for Transfusion Therapies, Collaborators. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013;53:2230-42. [DOI: 10.1111/trf.12175]
277. Pearce S, Rowe GP, Field SP. Screening of platelet for bacterial contamination at the Welsh Blood Service. Transfusion Medicine 2011;21(1):25-32.
278. Pendry K, Davies T. An audit of use and wastage in the north west of England and North Wales: where have all the platelets gone?. Blood and Transplant Matters 2011;34:17-9.
279. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-7.
280. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology 10;4:351-69.
281. The Nordic Cochrane Centre. Review Manager (RevMan). 5.3. Copenhagen: The Cochrane Collaboration, 2014.
282. Rysler C, Stoffel N, Buser A, Gratwohl A, Tsakiris DA, Stern M. Effect of beta-blockers, Ca2+antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets 2010;21(1):77-83.
283. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 2010;5(1):e8933. [DOI: 10.1371/journal.pone.0008933]
284. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology 2001;19:1519-38.
285. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
286. Segal HC, Briggs C, Kunka S, Casbard A, Harrison P, Machin SJ, et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. British Journal of Haematology 2005;128:520-5.
287. Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003;101(2):454-62.
288. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clinical Haematology 1978;7:523-39.
289. Slichter SJ. Controversies in platelet transfusion therapy. Annual Reviews of Medicine 1980;31:509-40.
290. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
291. Stanworth SJ, Dyer C, Choo L, Bakrania L, Copplestone A, Llewelyn C, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews 2010;24(3):163-71.
292. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
293. Sullivan MT, McCullough J, Schreiber GB, Wallace EL. Blood collection and transfusion in the United States in 1997. Transfusion 2002;42(10):1253-60.
294. Taylor C (Ed), Cohen H, Mold D, Jones H, et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT Report. SHOT Steering Group, 2010.
295. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; Vol. 8, issue 16. [DOI: 10.1186/1745-6215-8-16]
296. Tinmouth AT. Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. Canadian Blood Services. 4th Edition. Canadian Blood Services, 2007.
297. Verma A, Agarwal P. Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfusion and Apheresis Science 2009;41(2):145-9.
298. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48. Geneva: World Health Organization, 1979.
299. Zisk JL, Mackley A, Clearly G, Chang E, Christensen RD, Paul DA. Transfusing neonates based on platelet count vs. platelet mass: a randomized feasibility-pilot study. Platelets 2014;25(7):513-6.
300. Estcourt L, Stanworth SJ, Doree C, Hopewell S, Murphy MF, Tinmouth A, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3]
301. Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Murphy MF, et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD010983]
302. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2]